An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension - Wikidata - awgldk - TriplyDB

An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension

An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension

http://www.wikidata.org/entity/Q34557130

about

Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications Fragment Screening of Soluble Epoxide Hydrolase for Lead Generation-Structure-Based Hit Evaluation and Chemistry Exploration Soluble epoxide hydrolase: A potential target for metabolic diseases Soluble epoxide hydrolase inhibitors and heart failure Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy Targeting epoxides for organ damage in hypertension Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor Soluble epoxide hydrolase: a novel therapeutic target in stroke Effect of Soluble Epoxide Hydrolase on the Modulation of Coronary Reactive Hyperemia: Role of Oxylipins and PPARγ Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat Insulin resistance and endothelial dysfunction: Are epoxyeicosatrienoic acids the link?Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats Soluble epoxide hydrolase inhibition modulates vascular remodeling Soluble epoxide hydrolase in atherosclerosis Expression and regulation of soluble epoxide hydrolase in adipose tissue Epoxides and soluble epoxide hydrolase in cardiovascular physiology Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs Sexually dimorphic phenotype of arteriolar responsiveness to shear stress in soluble epoxide hydrolase-knockout mice 18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase (sEH)Development of a high-throughput screen for soluble epoxide hydrolase inhibition Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.Dietary omega-3 fatty acids aid in the modulation of inflammation and metabolic health.Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina

P2860

Q23910189-E423E48D-B80F-464E-AA5D-87BE227BE1E8 Q23911282-890C8046-8D8F-475D-A368-2143EF616061 Q23913693-53D7FEA6-77FF-4782-B97C-398FAB561DE3 Q24310374-660465B4-0871-4C7C-A7DD-950EE6DC7944 Q24597172-2DFF731A-EB9A-4E69-9DE1-85C7E313D8E9 Q24616753-60B7BEFF-9B65-412C-B5A6-51E7E0493665 Q27703977-A0258378-AF17-4D37-B7FF-3A38B9E0FEAD Q28270454-90F1A6DA-0C27-4314-A53F-81D989846572 Q28383423-E4F4B933-3552-40F6-A6E7-868DD937D517 Q28384279-79BD368D-50E3-461B-AB83-10C228E4FFC0 Q28385015-ACF6EED9-1325-4F77-A1D9-64EAC70E690D Q28386324-67EE992F-40C6-4874-8C78-2595CD9D30AE Q28387081-547839CB-C7BB-4F5E-85CA-EE73116BE6C2 Q28387558-534469A5-394A-4D76-BA6E-B2C81013E77B Q28387686-F18AE7A8-5A96-4541-8DA8-6A4E7647F11F Q28388145-B333B718-A78A-4DDB-A127-66257A6EA636 Q28388202-960C8B9B-9AB3-453C-AAA4-1A43B6E2A68C Q28389323-8D92DAF4-083E-4E29-9BC5-84D3EB615847 Q28390006-9B6ED02D-F069-4E01-8CFD-9428EA07EFCA Q28390132-65E866F3-4A3D-422A-8AA3-392E1AABFFB8 Q28390217-C06A7F6D-8F62-4664-A1A4-117C66655AA0 Q28390972-D416CC0F-E687-4A2B-8F8D-6FD7DA1F7DD6 Q28391163-FFE5011B-1E80-4846-B7F8-35F8D5140EFD Q28391533-BD054FB2-D062-4056-8333-E04E30488022 Q28392609-67484158-4E0E-4A04-B3DE-8D57F4757E03 Q28394250-10269FE1-E83E-42FE-A622-E90D621EAB61 Q28395004-4E2290EB-93BF-49A3-9A8E-EC444935A60F Q28395245-F5A6935E-FA46-4985-B56B-4B6159947A1F Q28396313-BFE657F6-7CA3-4AA6-AEDE-CB1B3B572EAB Q28396881-416769DF-A727-48AE-B1DF-A30E49C1C8EC Q28396888-A5443B2B-332F-45E9-8871-51A2CE883839 Q28398002-15FCC125-35D2-4A0D-BA15-CC549E7969AC Q29248913-0284E8A6-6C97-45F8-AEC0-281A4273D668 Q30816822-EFF6B35B-1A10-46A3-B0E2-8ACAF7D6D35E Q33605509-DBA167A7-656F-41DC-AC6C-567F64CC39B1 Q33648715-0CF8F335-DE96-47EB-9210-D61AECE3A348 Q33652488-54098F63-D898-4225-B531-5331849F3778 Q33731887-676ED055-D8D2-45A1-8892-8E68C610F126 Q33744236-68404A27-B385-4A7A-AEEF-FB454C7407F5 Q33761436-74D359B5-89F1-4C8E-AB7E-BE0EA59EF83D

P2860

An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension

http://www.wikidata.org/entity/Q34557130

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

An orally active epoxide hydro ...... in salt-sensitive hypertension

@ast

An orally active epoxide hydro ...... in salt-sensitive hypertension

@en

An orally active epoxide hydro ...... in salt-sensitive hypertension

@nl

type

label

An orally active epoxide hydro ...... in salt-sensitive hypertension

@ast

An orally active epoxide hydro ...... in salt-sensitive hypertension

@en

An orally active epoxide hydro ...... in salt-sensitive hypertension

@nl

prefLabel

An orally active epoxide hydro ...... in salt-sensitive hypertension

@ast

An orally active epoxide hydro ...... in salt-sensitive hypertension

@en

An orally active epoxide hydro ...... in salt-sensitive hypertension

@nl

P1433

Q34557130-63B77570-EFD8-4FB8-9597-77A8697C388B

P1476

Q34557130-429EADF3-6270-45EC-A143-4013F426D9B7

P2093

Q34557130-036ACF64-B89B-46C6-9E0C-57C2FFAEC18E

Q34557130-2C7CE475-66CE-4AB3-B4C8-C94FCF1F6918

Q34557130-4A8DD3BD-49D3-4ED4-AAA2-59AC1607470A

Q34557130-4DBAAF19-0EFD-4081-BDAA-6758C8A60CE3

Q34557130-4E31CD66-036C-4030-B42A-219F1DA5C7A4

Q34557130-A3935FD1-D4B6-4307-B9F0-5825AD60FBA5

Q34557130-A5BD1229-D40E-446C-97EA-832CB1CCCBB2

Q34557130-FE91E0FA-D919-4EBC-BF1B-DCD57FAEFEE0

P2860

Q34557130-07ABA0C3-A4D8-4C52-B2B0-9A2571772BB6

Q34557130-19A552C0-CF73-4438-AFCF-AEE5AEF6589B

Q34557130-1C9E290F-68BB-41F7-BC0E-AA0598D08A24

Q34557130-2D277345-C6B0-4106-B6FC-A266DF9A71C9

Q34557130-2DB6E6F8-FA05-40F9-B35E-ED606B653787

Q34557130-3C38F45A-F203-4CBD-98A4-E5470B29D71B

Q34557130-4513B36C-61E5-4F66-8999-7FF92047E792

Q34557130-47DEFE79-BE0C-44AF-8B00-C0D138E997D2

Q34557130-4CCBC2BD-91FE-47CD-A43E-EF549E8B51A3

Q34557130-5D2AFC3D-B7D2-4D63-8089-82CB48BF312E

P304

Q34557130-FBB4D421-8512-4B06-A3D2-4DE8DA861D96

P31

Q34557130-74F3C936-73C7-4609-BB47-1F9F70A15E95

P356

Q34557130-F67BFE30-E4D5-4864-BFF5-C74FC10F2028

P407

Q34557130-04B88E42-8455-4031-AE77-41F6FB2B6FAE

P433

Q34557130-A7F50FB2-1B24-42C2-88CA-AFEC9D165E9E

P478

Q34557130-FFA83DC0-8A2A-4118-AC63-710B42C66845

P50

Q34557130-099B58FE-772A-4E36-B2D3-9C42CED710C3

P577

Q34557130-45BF018B-CCD4-4BDA-BA68-DCE9F8849AEE

P698

Q34557130-A6E3B7FC-7267-4EE8-9D5C-AA729A63EE23

P932

Q34557130-D840AB10-FC14-4857-BF4D-6AC37AD5D094

P356

01.HYP.0000176237.74820.75

P1433

P1476

An orally active epoxide hydro ...... in salt-sensitive hypertension

@en

P2093

Bruce D Hammock

http://www.w3.org/2001/XMLSchema#string

Constantine Z Zaharis

http://www.w3.org/2001/XMLSchema#string

David M Pollock

http://www.w3.org/2001/XMLSchema#string

In-Hae Kim

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Olearczyk

http://www.w3.org/2001/XMLSchema#string

John D Imig

http://www.w3.org/2001/XMLSchema#string

Takaho Watanabe

http://www.w3.org/2001/XMLSchema#string

Xueying Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway

Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet

Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II

Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension

P-450 metabolites of arachidonic acid in the control of cardiovascular function

The epidemic of cardiovascular disease in end-stage renal disease.

Eicosanoid regulation of the renal vasculature.

Immunosuppressive treatment protects against angiotensin II-induced renal damage

Inclusion of albuminuria in hypertension and heart guidelines.

Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats.

P304

975-981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.HYP.0000176237.74820.75

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16157792

http://www.w3.org/2001/XMLSchema#string

P932

1444888

http://www.w3.org/2001/XMLSchema#string